Risk Stratification in Metabolic Dysfunction-Associated Steatohepatitis: Early Versus Late Fibrosis

Nov 10 2025
Convention Center: Room 146B, Level 1
3:45 PM - 4:45 PM

World Class Speakers

Amreen Dinani, MD FRCPC
Panelist

Amreen Dinani, MD FRCPC

Duke University School of Medicine
IR
Moderator

Ian A Rowe, PhD

University of Leeds
Alina M. Allen, MD
Moderator

Alina M. Allen, MD

Mayo Clinic Rochester

Description

Experts examine the importance of fibrosis staging in the risk assessment and management of metabolic-associated steatohepatitis (MASH). The session explores the clinical implications of focusing on early-stage versus late-stage fibrosis; evaluates the role of advanced diagnostic tools in stratifying risk; and reviews how targeted approaches can improve patient outcomes. This community conversation aims to impart a deeper understanding of how to prioritize interventions based on fibrosis severity and emerging evidence.

Journey Maps

Presentations

3:45 PM - 4:05 PM
Nov 10 2025
Washington, D.C.

Risk Stratification for Early Metabolic Dysfunction-Associated Steatohepatitis

Alina M. Allen, MD, Presenter
MASLD
4:05 PM - 4:25 PM
Nov 10 2025
Washington, D.C.

Risk Stratification for Late Metabolic Dysfunction-Associated Steatohepatitis

Ian A Rowe, PhD, Presenter
MASLD
8:31 PM - 8:31 PM
Nov 10 2025
Washington, D.C.

Panel Discussion

Amreen Dinani, MD FRCPC, Panelist
MASLD

Objectives

  • Review the impact of early-stage versus late-stage fibrosis on disease progression, patient management, and prognosis in MASH.
  • Assess advanced diagnostic tools and techniques, including noninvasive technologies, and their application in stratifying patients by fibrosis stage.
  • Identify tailored risk stratification approaches to optimize treatment plans and resource allocation based on fibrosis stage and patient needs.